Trial Profile
InductOs (rhBMP-2; dibotermin alfa) vs. autologous bone grafting for the treatment of nonunion of the docking site in tibial bone transport
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 28 Sep 2022
Price :
$35
*
At a glance
- Drugs Dibotermin alfa (Primary)
- Indications Non-union fracture
- Focus Therapeutic Use
- 15 Jul 2016 New trial record